This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Rowan, P. R.
Right arrow Articles by Parker, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowan, P. R.
Right arrow Articles by Parker, R. R.

The British Journal of Psychiatry 140: 475-483 (1982)
© 1982 The Royal College of Psychiatrists

Phenelzine and amitriptyline: effects on symptoms of neurotic depression

PR Rowan, ES Paykel and RR Parker

A double-blind controlled trial of phenelzine, amitriptyline and placebo was carried out in out-patients suffering from depression or mixed anxiety and depression. After six weeks treatment both active drugs were clearly superior to placebo and of similar efficacy; therapeutic effects started to appear at two weeks. Comparisons on symptom ratings showed that both drugs acted as true antidepressants, producing their greatest effects on ratings of depressive mood and thought content. There were additional weak differences, phenelzine producing more improvement on anxiety ratings, while amitriptyline gave greater effects on depressive impairment of work and interests and anergia. Analyses showed little evidence of clinical subgroups responding preferentially to either drug. The findings indicate that MAO inhibitors and tricyclic antidepressants have more closely similar clinical effects than has been thought and that either may be a useful treatment for these patients who are often considered to respond poorly to antidepressant drug treatment.


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
A. L. Malizia and P. K. Bridges
The management of treatment-resistant affective disorder: clinical perspectives
J Psychopharmacol, January 1, 1992; 6(2): 145 - 155.
[PDF]

Home page
 Arch Gen PsychiatryHome page
F. M. Quitkin, W. Harrison, J. W. Stewart, P. J. McGrath, E. Tricamo, K. Ocepek-Welikson, J. G. Rabkin, S. G. Wager, E. Nunes, and D. F. Klein
Response to Phenelzine and Imipramine in Placebo Nonresponders With Atypical Depression: A New Application of the Crossover Design
Arch Gen Psychiatry, April 1, 1991; 48(4): 319 - 323.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
F. M. Quitkin, P. J. McGrath, J. W. Stewart, W. Harrison, E. Tricamo, S. G. Wager, K. Ocepek-Welikson, E. Nunes, J. G. Rabkin, and D. F. Klein
Atypical Depression, Panic Attacks, and Response to Imipramine and Phenelzine: A Replication
Arch Gen Psychiatry, October 1, 1990; 47(10): 935 - 941.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
F. M. Quitkin, P. J. McGrath, J. W. Stewart, W. Harrison, S. G. Wager, E. Nunes, J. G. Rabkin, E. Tricamo, J. Markowitz, and D. F. Klein
Phenelzine and Imipramine in Mood Reactive Depressives: Further Delineation of the Syndrome of Atypical Depression
Arch Gen Psychiatry, September 1, 1989; 46(9): 787 - 793.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. R. Joyce and E. S. Paykel
Predictors of Drug Response in Depression
Arch Gen Psychiatry, January 1, 1989; 46(1): 89 - 99.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. R. T. Davidson, E. L. Giller, S. Zisook, and J. E. Overall
An Efficacy Study of Isocarboxazid and Placebo in Depression, and Its Relationship to Depressive Nosology
Arch Gen Psychiatry, February 1, 1988; 45(2): 120 - 127.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. R. Liebowitz, F. M. Quitkin, J. W. Stewart, P. J. McGrath, W. M. Harrison, J. S. Markowitz, J. G. Rabkin, E. Tricamo, D. M. Goetz, and D. F. Klein
Antidepressant Specificity in Atypical Depression
Arch Gen Psychiatry, February 1, 1988; 45(2): 129 - 137.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
E.S. Paykel
Antidepressants: Their efficacy and place in therapy
J Psychopharmacol, January 1, 1988; 2(3-4): 105 - 118.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
P. Tyrer, C.A. Marsden, P. Casey, and N. Seivewright
Clinical efficacy of paroxetine in resistant depression
J Psychopharmacol, January 1, 1987; 1(4): 251 - 257.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. R. Liebowitz, F. M. Quitkin, J. W. Stewart, P. J. McGrath, W. Harrison, J. Rabkin, E. Tricamo, J. S. Markowitz, and D. F. Klein
Phenelzine v Imipramine in Atypical Depression: A Preliminary Report
Arch Gen Psychiatry, July 1, 1984; 41(7): 669 - 677.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
F. M. Quitkin, J. G. Rabkin, D. Ross, and P. J. McGrath
Duration of Antidepressant Drug Treatment: What Is an Adequate Trial?
Arch Gen Psychiatry, March 1, 1984; 41(3): 238 - 245.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
E. S. Paykel, P. R. Rowan, R. R. Parker, and A. V. Bhat
Response to Phenelzine and Amitriptyline in Subtypes of Outpatient Depression
Arch Gen Psychiatry, September 1, 1982; 39(9): 1041 - 1049.
[Abstract] [PDF]